Skip to content
Screener

Total Equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$84.97B+8.3%
United Community Banks logo
United Community BanksUCB
$3.75B+3.7%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$662.1M+28.5%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$545.93M+58.5%
Immunome logo
ImmunomeIMNM
$588.69M+91.7%
Vera Therapeutics logo
Vera TherapeuticsVERA
$499.7M-6.6%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.11B+197%
Enterprise value$7.21B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemMarch 31, 2026March 31, 2025
Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at March 31, 2026 and March 31, 2025
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2026 and March 31, 2025
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 20252016
Additional paid-in capital2,596,9711,945,495
Accumulated other comprehensive income7301,459
Accumulated deficit(1,745,129)(1,239,523)
Total stockholders’ equity852,592707,447
Total liabilities and stockholders’ equity$957,014$776,222

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s total equity?
Immunovant, Inc. (IMVT) reported total equity of $852.59M in Q1 2026.
How has Immunovant, Inc.'s total equity changed year-over-year?
Immunovant, Inc.'s total equity increased by 20.5% year-over-year, from $707.45M to $852.59M.
What is the long-term trend for Immunovant, Inc.'s total equity?
Over 5 years (2021 to 2026), Immunovant, Inc.'s total equity has grown at a 16.8% compound annual growth rate (CAGR), from $391.48M to $852.59M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Immunovant, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude